Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.70 |
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | GAA | P10253 | 4/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | APP | P05067 | 8/20 | 0.66 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11000856 | 0.89 | MAPT (0.60) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL2203669 | 0.87 | MAPT (0.77) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL4325917 | 0.82 | MAPT (1.00) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL4661670 | 0.82 | MAPT (0.70) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL31420004 | 0.82 | MAPT (0.70) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL16900694 | 0.82 | MAPT (0.70) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL3529446 | 0.82 | MAPT (0.70) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL118345 | 0.82 | MAPT (0.97) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| Edaravone SCHEMBL4704 | 0.81 | KMT2A (1.00) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL8625650 | 0.81 | MAPT (1.00) | MAPTKMT2AMEN1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118754890-A | Isochroman spiro pyrazolone compound and preparation method thereof | 天津科技大学 | 2024-10-11 | — | — | CN | disclosed |
| CN-118345388-A | Method for preparing pyrazolone substituted quinoxalinone derivative through electrochemical promotion | 桂林理工大学 | 2024-07-16 | — | — | CN | disclosed |
| CN-111440181-B | Dipyrazolo seven-membered oxygen heterocyclic compound containing quinoline structure and synthetic method thereof | 烟台大学 | 2023-03-21 | — | — | CN | disclosed |
| US-20210128529-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | NOBELPHARMA CO., LTD. (JP) | 2021-05-06 | — | — | US | disclosed |
| CN-112118839-A | Pyrazolone derivative-containing drug | 耐贝医药株式会社 | 2020-12-22 | — | — | CN | disclosed |
| EP-3666270-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | Nobelpharma Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110862383-A | Histone acetyltransferase P300 small-molecule inhibitor, medicinal composition thereof and application thereof | 复旦大学 | 2020-03-06 | — | — | CN | disclosed |
| EP-1793821-B1 | PYRAZOLONE COMPOUNDS FOR TREATING CEREBROVASCULAR DISORDERS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-10004720-B2 | Agent for preventing and/or treating ophthalmologic diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-06-26 | — | — | US | disclosed |
| EP-3321255-A1 | NOVEL THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) OR DISEASE ATTRIBUTABLE TO ALS | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
| EP-1437137-A1 | DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE | Mitsubishi Pharma Corporation (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435894-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003009807-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO LABORATORIES, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
| US-RE35801-E | PYRAZOLONE DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0208874-B1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR CIRCULATORY DISORDERS | MITSUBISHI KASEI CORPORATION (JP) | 1993-03-24 | — | — | EP | disclosed |
| US-4857542-A | INHIBITOR AGAINST LIPID PEROXIDATION | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0208874-A1 | Prophylactic and therapeutic agent for circulatory disorders | MITSUBISHI KASEI CORPORATION (JP) | 1987-01-21 | — | — | EP | disclosed |
| US-4537886-A | β-lactam antibacterial agents and compositions containing them | BEECHAM GROUP P.L.C. (GB) | 1985-08-27 | — | — | US | disclosed |
| EP-0090656-A1 | Penicillins, a process for the preparation and compositions containing them | BEECHAM GROUP PLC (GB) | 1983-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | MAPT 2548/4885KMT2A 4665/4885MEN1 3991/4885 |
| US-20210128529-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | CYP11B2, CYP3A5, DPYD | MAPT 4271/4885KMT2A 1306/4885MEN1 3967/4885 |
| US-10004720-B2 | Agent for preventing and/or treating ophthalmologic diseases | MITF, EYA3, AQP1 | MAPT 2342/4885KMT2A 2873/4885MEN1 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.